Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
Sign Up to like & getrecommendations! Published in 2021 at "Vaccine"
DOI: 10.1016/j.vaccine.2021.05.090
Abstract: A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4 chimeric vaccine construct was designed… read more here.
Keywords: hiv; cd4 chimeric; gp120 cd4; vaccine ... See more keywords
Evaluation of phytopolyphenols for their gp120-CD4 binding inhibitory properties by in silico molecular modelling & in vitro cell line studies.
Sign Up to like & getrecommendations! Published in 2019 at "Current HIV research"
DOI: 10.2174/1570162x17666190611121627
Abstract: BACKGROUND Lack of effective early-stage HIV-1 inhibitor instigated the need for screening of novel gp120-CD4 binding inhibitor. Polyphenols, a secondary metabolite derived from natural sources are reported to have broad spectrum HIV-1 inhibitory activity. However,… read more here.
Keywords: cell line; line studies; vitro cell; gp120 cd4 ... See more keywords